When a sponsor with a Phase III melanoma study came to Worldwide, they faced rapid timelines in a highly competitive indication paired with a high site burden due to its selection criteria. How did Worldwide address these challenges? Find out in our case study: https://ow.ly/EZiS50Sxe36
Worldwide Clinical Trials’ Post
More Relevant Posts
-
Going to EHA 2024? Connect with us to learn more about our tailored reports from the leading source of European oncology data. https://ow.ly/rCCm30sCZRl #EHA2024 #OncologyData #RealWorldResearch
-
-
Vice President Operations @ TriNetX Oncology GmbH ¦ Managing Director @ CancerDataNet GmbH
Going to EHA 2024? Connect with us to learn more about our tailored reports from the leading source of European oncology data. https://ow.ly/CXtg30sCE8F #EHA2024 #OncologyData #RealWorldResearch
-
-
Vice President Operations @ TriNetX Oncology GmbH ¦ Managing Director @ CancerDataNet GmbH
Going to EHA 2024? Connect with us to learn more about our tailored reports from the leading source of European oncology data. https://ow.ly/aLsR30sE7SS #EHA2024 #OncologyData #RealWorldResearch
-
-
Medical Director | Medical Affairs | Physician Consultant | Cell & Gene Therapy Advisor | Drug Safety Physician — Hematology, Oncology & Rare Diseases
Are you aware of the recent implementation of the EU Clinical Trials Regulation No 536/2014 and how that will affect your oncology program? Find out in my team members’ blog: Navigating the Complex Regulatory CRO Landscape for Oncology Trials in the EU https://bit.ly/3WEcxga
-
-
Going to EHA 2024? Connect with us to learn more about our tailored reports from the leading source of European oncology data. https://ow.ly/Xghb30sCYuX #EHA2024 #OncologyData #RealWorldResearch
-
-
Learn how Calyx #IRT tackles the unique #RTSM challenges #Oncology trial sponsors face to keep #ClinicalTrials on track. Access papers, webinars, and other resources here! https://lnkd.in/ggM4FTs3 #ChooseCalyx #Randomization #TrialSupplyManagement
Overcoming RTSM Challenges in Oncology Trials | Resources from Calyx IRT
calyx.dsmn8.com
-
Exciting News 📢 Taiho Oncology, Inc. unveils groundbreaking results from the ASCERTAIN trial of INQOVI® for MDS and CMML. 📊 The first Phase 3 trial to show equivalence between oral and IV formulations, with a 32-month median overall survival and 62% overall response rate. Read the full article here: https://bit.ly/4b9mN5c #CancerResearch #MDSTreatment #ClinicalTrials #ClinicalResearch
-
-
From trial harmonization to economic impact, check out our white paper for a comprehensive and actionable guide for integrating PROs into your oncology program. https://bit.ly/490C2uZ
Read Our White Paper: The Emergence of PROs in Oncology
worldwide.voicestorm.com
-
LMS Administrator at Worldwide Clinical Trials / e-Learning / Learning Management Systems / Adult Education/ Digital Education
From trial harmonization to economic impact, check out our white paper for a comprehensive and actionable guide for integrating PROs into your oncology program. https://bit.ly/490C2uZ
Read Our White Paper: The Emergence of PROs in Oncology
worldwide.voicestorm.com
-
From trial harmonization to economic impact, check out our white paper for a comprehensive and actionable guide for integrating PROs into your oncology program. https://bit.ly/490C2uZ
Read Our White Paper: The Emergence of PROs in Oncology
worldwide.voicestorm.com
Felix Perez, CEO Research Director
1moImpressive strides in overcoming challenges! Worldwide's approach to Phase III melanoma study timelines and site burden is a must-read for insights into effective trial management.